COVID-19 Research Paper Volume 12, Issue 22 pp 22413—22424
Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities
Figure 1. Differences in the T-lymphocyte subsets in severe COVID-19 patients with and without chronic comorbidities. (A) Significant decreases in the proportion of CD4+T cells was observed in the comorbidities group. (B) There was no significant difference in CD8+ or (C) CD3+ T cell proportions between the comorbidities and non-comorbidities groups.